{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DS+Stage+III+Multiple+Myeloma", "query": { "condition": "DS Stage III Multiple Myeloma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DS+Stage+III+Multiple+Myeloma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T01:23:58.765Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01251172", "title": "RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Hematopoietic Stem Cell Mobilization", "type": "PROCEDURE" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01251172" }, { "nct_id": "NCT00088855", "title": "Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2004-06-15", "completion_date": "2008-01-08", "has_results": false, "last_update_posted_date": "2019-09-23", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 25, "location_summary": "Mountain View, California • Newark, Delaware • Washington D.C., District of Columbia + 19 more", "locations": [ { "city": "Mountain View", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088855" }, { "nct_id": "NCT01330173", "title": "Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330173" }, { "nct_id": "NCT00114101", "title": "Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "DS Stage I Multiple Myeloma", "DS Stage II Multiple Myeloma", "DS Stage III Multiple Myeloma", "Refractory Multiple Myeloma", "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 460, "start_date": "2004-12-15", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 140, "location_summary": "Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00114101" }, { "nct_id": "NCT01028716", "title": "Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Erythroid Leukemia in Remission", "Acute Leukemia in Remission", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome", "Acute Myeloid Leukemia in Remission", "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1", "Acute Myeloid Leukemia With Multilineage Dysplasia", "Acute Myeloid Leukemia With t(6;9)", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Complete Remission", "B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)", "Ph+ ALL", "Burkitt Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Complete Remission", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Myelodysplastic Syndrome", "Recurrent Anaplastic Large Cell Lymphoma", "Blasts Under 5 Percent of Bone Marrow Nucleated Cells", "Recurrent Follicular Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma", "Secondary Acute Myeloid Leukemia", "T Lymphoblastic Lymphoma", "Hematopoietic Cell Transplant Recipient" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 46, "start_date": "2010-05-19", "completion_date": "2021-10-07", "has_results": true, "last_update_posted_date": "2023-01-23", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01028716" }, { "nct_id": "NCT00445692", "title": "Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-01-10", "completion_date": "2017-04-24", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00445692" }, { "nct_id": "NCT01619761", "title": "NK Cells in Cord Blood Transplantation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Biphenotypic Leukemia", "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia in Remission", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "ISS Stage II Plasma Cell Myeloma", "ISS Stage III Plasma Cell Myeloma", "Myelodysplastic Syndrome", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Umbilical Cord Blood Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 13, "start_date": "2013-05-03", "completion_date": "2021-11", "has_results": false, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01619761" }, { "nct_id": "NCT01668719", "title": "S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2012-11", "completion_date": "2025-09-22", "has_results": true, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 417, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01668719" }, { "nct_id": "NCT01605032", "title": "Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 19, "start_date": "2012-02", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • New York, New York • The Bronx, New York", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605032" }, { "nct_id": "NCT00869206", "title": "Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Adenocarcinoma", "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "Metastatic Malignant Neoplasm to the Bone", "Pain", "Musculoskeletal Complication", "Urinary Complications" ], "interventions": [ { "name": "zoledronic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1822, "start_date": "2009-03", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-11-07", "last_synced_at": "2026-06-11T01:23:58.765Z", "location_count": 503, "location_summary": "Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Fairfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869206" } ] }